Subscribe
shutterstock_716579470_nespix-1
NESPIX / Shutterstock.com
14 August 2019AmericasSarah Morgan

Jazz Pharma buys clinical-stage biotech company

Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Jazz Pharma accused of pay-for-delay deals over Xyrem
14 October 2021   Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Generics
Jazz Pharma accused of pay-for-delay deals over Xyrem
14 October 2021   Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

More on this story

Generics
Jazz Pharma accused of pay-for-delay deals over Xyrem
14 October 2021   Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart-Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes